1. Home
  2. VOXR vs ALLO Comparison

VOXR vs ALLO Comparison

Compare VOXR & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vox Royalty Corp.

VOXR

Vox Royalty Corp.

HOLD

Current Price

$4.60

Market Cap

293.7M

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOXR
ALLO
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.7M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
VOXR
ALLO
Price
$4.60
$1.49
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$8.60
AVG Volume (30 Days)
684.4K
2.9M
Earning Date
02-19-2026
11-06-2025
Dividend Yield
1.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,158,304.00
N/A
Revenue This Year
$42.80
N/A
Revenue Next Year
$82.76
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
9.06
N/A
52 Week Low
$2.21
$0.86
52 Week High
$5.54
$3.78

Technical Indicators

Market Signals
Indicator
VOXR
ALLO
Relative Strength Index (RSI) 41.26 59.13
Support Level $4.44 $1.30
Resistance Level $4.91 $1.54
Average True Range (ATR) 0.21 0.09
MACD -0.08 0.00
Stochastic Oscillator 15.31 85.71

Price Performance

Historical Comparison
VOXR
ALLO

About VOXR Vox Royalty Corp.

Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: